Abstract
Amyloid beta peptide (Aβ) is implicated in the pathogenesis of Alzheimers disease (AD), particularly as oligomers or polymers that are correlated with Ab cellular toxicity. Inhibition of the formation of toxic forms of Aβ has therefore emerged as one approach to the treatment of AD. This article reviews efforts to adapt the structure of Aβ to the design and testing of peptide-based inhibitors of Aβ polymerization of interest as potential AD therapeutics.
Keywords: Peptide Inhibitors, Beta Amyloid Aggregation, Amyloid beta peptide
Current Topics in Medicinal Chemistry
Title: Peptide Inhibitors of Beta Amyloid Aggregation
Volume: 2 Issue: 4
Author(s): Mark A. Findeis
Affiliation:
Keywords: Peptide Inhibitors, Beta Amyloid Aggregation, Amyloid beta peptide
Abstract: Amyloid beta peptide (Aβ) is implicated in the pathogenesis of Alzheimers disease (AD), particularly as oligomers or polymers that are correlated with Ab cellular toxicity. Inhibition of the formation of toxic forms of Aβ has therefore emerged as one approach to the treatment of AD. This article reviews efforts to adapt the structure of Aβ to the design and testing of peptide-based inhibitors of Aβ polymerization of interest as potential AD therapeutics.
Export Options
About this article
Cite this article as:
Findeis A. Mark, Peptide Inhibitors of Beta Amyloid Aggregation, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607508
DOI https://dx.doi.org/10.2174/1568026024607508 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantification of Glycyrrhetic Acid in Human Plasma by LC–MS/MS: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Peripheral Corticotropin Releasing Factor Signaling Inhibits Gastric Emptying: Mechanisms of Action and Role in Stress-related Gastric Alterations of Motor Function
Current Pharmaceutical Design Suicide in Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies
Combinatorial Chemistry & High Throughput Screening Identification of High Affinity Bioactive Salbutamol Conformer Directed Against Mutated (Thr164Ile) Beta 2 Adrenergic Receptor
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) What About the Neuroimaging Findings in Social Anxiety Disorder?
Reviews on Recent Clinical Trials Transition States and Inhibitors of the Purine Nucleoside Phosphorylase Family
Current Topics in Medicinal Chemistry Determination of Propranolol and Naproxen in Urine by using Excitation-Emission Matrix Phosphorescence Coupled with Multivariate Calibration Algorithms
Current Pharmaceutical Analysis Aquaporins and Glia
Current Neuropharmacology From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones
Mini-Reviews in Medicinal Chemistry Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets